Abstract: Objective The aim of this study was to explore the efficacy of transhepatic artery autologous bone marrow stem cell (BMSC) transplantation in the treatment of patients with hepatitis B-induced acute-on-chronic liver failure (HBV-ACLF). Methods 94 patients with HBV-ACLF were recruited in the Department of Hepatorenal Medicine of our hospital between May 2017 and December 2018, and were randomly divided into control (n=47) and observation group (n=47). All the patients were treated with comprehensive medical supporting treatment and plasma dialysis filtration (PDF), while those in the observation group were treated with transhepatic artery autologous BMSC transplantation at the base of PDF. All the patients were followed-up for 12 months. The Eastern cooperative oncology group (ECOG) scores and model for end-stage liver diseases (MELD) were evaluated. Results At the end of 24 week and 48 week treatment, the survival rates in the combination group were 72.3% and 53.2%, significantly higher than 48.9% and 31.9%(P<0.05) in the control; at the end of 24 week, serum albumin levels in 34 survival in the combination group was (35.8±3.9)g/L, much higher than 【(32.3±3.5)g/L, P<0.05】 in 25 survival in the control; at the end of 24 week and 48 week, the incidences of ECOG score greater than 2 were 26.5% and 12.0%, significantly lower than 56.5% and 40.0%(P<0.05) in the control; at the end of 48 week, the MELD score was (9.7±1.3), significantly lower than 【(11.4±1.5), P<0.05】 in the control. Conclusion The autologous bone marrow stem cell transplantation through hepatic artery at the base of comprehensive supporting measures might improve the albumin synthesis and raise the survival rates in patients with HBV-ACLF, which needs further investigation of its long-term efficacy.

Key words: Acute-on-chronic liver failure, Hepatitis B, Autologous bone marrow stem cell transplantation, Plasma dialysis filtration, Eastern cooperative oncology group, Model for end-stage liver diseases, Efficacy